As we start 2021, let’s look at where things currently stand with the Beovu “safety issue” — Beovu adverse drug reactions and Beovu-related eye problems — and how we got here. In the 15 months since Beovu was approved by the FDA in October 2019, there have been numerous reports of Beovu causing occlusive retinal vasculitis, retinal artery … [Read more...]
Beovu Retinal Vasculitis Made Worse by a Later Lucentis Treatment
A recent medical journal article presents an interesting case report about a 76-year-old woman with Beovu-related retinal vasculitis which was made worse by a later Lucentis treatment for her wet AMD. That patient's doctors are the authors of "Brolucizumab-related retinal vasculitis with exacerbation following ranibizumab retreatment: A … [Read more...]
Beovu-related Retinal Vasculitis and Beovu Vision Loss Cases
As of December 2020, the investigation continues to find the root causes of Beovu-related retinal vasculitis which seems to be involved in many of the growing numbers of Beovu vision loss cases. At the same time retina specialists and other eye doctors are still trying to determine the best medical management or treatment methods for Beovu patients … [Read more...]
Beovu Legal Cases: Compensation for Eye Problems from Beovu Use
Our law firm is investigating possible Beovu lawsuits for patients who have been diagnosed with vision loss, blindness, or other serious eye problems which are Beovu side effects. Such drug injury Beovu legal cases might involve one or more of the following Beovu eye-related side effects: Vision LossBlindnessOcclusive Retinal VasculitisRetinal … [Read more...]
Beovu-associated Endophthalmitis is “New” for Beovu Eye Drug Safety Issue of Vision Loss
In this article, we will look at the Beovu-associated endophthalmitis and Beovu-associated retinal detachment aspects of the Beovu eye drug safety issue of vision loss. New warnings for these vision-related side effects were added in June 2020 when Novartis revised the Prescribing Information for Beovu. In the Beovu drug label, or “Full … [Read more...]
Beovu Use Continues Despite Ongoing Beovu-associated Inflammation Investigation
A summary of the Beovu-associated inflammation safety issue is presented in this July 2020 Journal of VitreoRetinal Diseases Research Article, “Occlusive Retinal Vasculitis Following Intravitreal Brolucizumab”. From the Abstract for this item we get these details about the current Beovu safety issue under investigation: Conclusions: … [Read more...]
Safety of Beovu Update: Study Results Announcement by Novartis and Beovu Label Change in Europe
A September 2020 announcement by Novartis about recent Beovu study results had an emphasis on the safety of Beovu. However, this is understandable in view of a February 2020 notification issued by the American Society of Retina Specialists (ASRS) which raised questions about the safety of Beovu. We get the following from this September 14, … [Read more...]
Beovu: External Safety Review Committee Findings Lead To New Vision-Related Side Effects Warnings
First, Novartis set up an internal review of Beovu vision-related side effects observed in the HAWK & HARRIER clinical trials, including rare post-marketing safety reports of vasculitis. In turn, new warnings for Beovu eye injections about retinal vasculitis and retinal vascular occlusion were added to the Beovu drug label. We take a closer … [Read more...]
Beovu Vision Loss And Retinal Vasculitis Cases May Lead To New Warnings
There have been reports of severe vision loss associated with Beovu injections as well as cases of vasculitis linked to Beovu. In March 2020 Novartis stated that the current Beovu Prescribing Information document sufficiently addressed Beovu risks of intraocular inflammation and retinal artery occlusion. However, Novartis recently said that … [Read more...]
Beovu Warning For Retinal Vasculitis: Is Current Drug Label Sufficient “As Is”?
In late February 2020 the American Society of Retina Specialists (ASRS) seemed to assert in a notification about the macular degeneration drug Beovu that there needs to be a stronger warning about retinal vasculitis as a Beovu side effect. In early March 2020 Novartis retorted that the current Prescribing Information document for Beovu … [Read more...]